Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis

Basic Details
Date Posted
Friday, June 24, 2022
Status
Complete
Medical Product
bamlanivimab
bamlanivimab etesevimab
casirivimab imdevimab
Health Outcome(s)
utilization
Description

In this report we examined counts of individuals using the monoclonal antibodies (mAbs) under an Emergency Use Authorization (EUA) in the Rapid Coronavirus Disease 2019 (COVID‐19) Sentinel Distributed Database (SDD).

The study period includes data from November 1, 2020 to January 31, 2021. We distributed this request to three Sentinel Data Partners on July 28, 2021.

Deliverables (1)
Sentinel Modular Program Report: Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
November 1, 2020 - January 31, 2021
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
All individuals
Data Sources
Rapidly Refreshed Sentinel Distributed Database (rSSD)
Related Links
Sentinel Drug Analysis: Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis
Sentinel Drug Analysis: Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis